Abstract
The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
Keywords: EGFR, HER2, mIRs, Cancer Stem Cells, Drug Resistance, Metastasis.
Current Pharmaceutical Design
Title:Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Volume: 22 Issue: 16
Author(s): Dariusz Rakus, James A. McCubrey, Stephen L. Abrams, Zoya Demidenko, Agustino Tafuri, Michelle Milella, Melchiorre Cervello, Giuseppe Montalto, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Joerg Basecke, Joanna Dulinska-Litewka, Piotr Laidler, Agnieszka Gizak, Linda S. Steelman, Lyudmyla Drobot, Concettina Fenga, Aurora Scalisi, Ferdinando Nicoletti, Saverio Candido, Massimo Libra, Sandra Marmiroli, Luca M. Neri, Alberto M. Martelli, Matilde Y. Follo, Lucio Cocco, Kvin Lertpiriyapong and Timothy Fitzgerald
Affiliation:
Keywords: EGFR, HER2, mIRs, Cancer Stem Cells, Drug Resistance, Metastasis.
Abstract: The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
Export Options
About this article
Cite this article as:
Rakus Dariusz, McCubrey A. James, Abrams L. Stephen, Demidenko Zoya, Tafuri Agustino, Milella Michelle, Cervello Melchiorre, Montalto Giuseppe, Maksimovic-Ivanic Danijela, Mijatovic Sanja, Basecke Joerg, Dulinska-Litewka Joanna, Laidler Piotr, Gizak Agnieszka, Steelman S. Linda, Drobot Lyudmyla, Fenga Concettina, Scalisi Aurora, Nicoletti Ferdinando, Candido Saverio, Libra Massimo, Marmiroli Sandra, Neri M. Luca, Martelli M. Alberto, Follo Y. Matilde, Cocco Lucio, Lertpiriyapong Kvin and Fitzgerald Timothy, Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160304151011
DOI https://dx.doi.org/10.2174/1381612822666160304151011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multi-Target Mining of Alzheimer Disease Proteome with Hansch’s QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline
Current Drug Targets Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Estrogenic Phenol and Catechol Metabolites of PCBs Modulate Catechol-Omethyltransferase Expression Via the Estrogen Receptor: Potential Contribution to Cancer Risk
Current Drug Metabolism Towards Improved Therapies Using Nanopharmaceuticals: Recent Patents on Pharmaceutical Nanoformulations
Recent Patents on Food, Nutrition & Agriculture Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach
Current Pharmaceutical Design Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine Plant-Derived Products as Antibacterial and Antifungal Agents in Human Health Care
Current Medicinal Chemistry Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics Designing and Formulation Optimization of Hyaluronic Acid Conjugated PLGA Nanoparticles of Tamoxifen for Tumor Targeting
Pharmaceutical Nanotechnology Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets ACO Inspired Computer-aided Detection/Diagnosis (CADe/CADx) Model for Medical Data Classification
Recent Patents on Computer Science Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Skin Repair Properties of d-Limonene and Perillyl Alcohol in Murine Models
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Heme Oxygenase-1 and Breast Cancer Resistance Protein Protect Against Hemeinduced Toxicity
Current Pharmaceutical Design DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Current Pharmaceutical Design